natgillin/translations-raw huggingface dataset:
Tonocalcin solution for injection intramuscular use, subcutaneous use 
Tonocalcin raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
CALCO 50 NE/ml injekció solution for injection subcutaneous use, intramuscular use, intravenous use 
CALCO 50 NE/ml injekció raztopina za injiciranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
Calcitonin Stada 50 I.E. Injektionslösung solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin Stada 50 I.E. Injektionslösung raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calcitonin-ratiopharm 100 I.E. Ampullen solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin-ratiopharm 100 I.E. Ampullen raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calcitonine Pharmy II 50 IU/ml solution for injection intramuscular use, intravenous use, subcutaneous use 
Calcitonine Pharmy II 50 i.e./ml raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Calcitonine Pharmy II 100 IU/ml solution for injection intramuscular use, intravenous use, subcutaneous use 
Calcitonine Pharmy II 100 i.e./ml raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
MIACALCIC 50 NE/ml oldatos injekció és infúzió solution for injection/infusion subcutaneous use, intramuscular use, intravenous use 
MIACALCIC 50 NE/ml oldatos injekció és infúzió raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
MIACALCIC 100 NE/ml oldatos injekció és infúzió solution for injection/infusion subcutaneous use, intramuscular use, intravenous use 
MIACALCIC 100 NE/ml oldatos injekció és infúzió raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
Osteos 100 I.E./ml solution for injection intravenous use, intramuscular use, subcutaneous use 
Osteos 100 I.E./ml raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calcitonin-ratiopharm 50 I.E. Ampullen solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin-ratiopharm 50 I.E. Ampullen raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calcitonin-CT 50 I.E./ml Ampullen solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin-CT 50 I.E./ml Ampullen raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calcitonin-CT 100 I.E./ml Ampullen solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin-CT 100 I.E./ml Ampullen raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Osteos 50 I.E./ml solution for injection intravenous use, intramuscular use, subcutaneous use 
Osteos 50 I.E./ml raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Miacalcic 50 IU/1 ml solution for injection, concentrate for solution for infusion subcutaneous use, intramuscular use, intravenous use 
Miacalcic 50 IU/1 ml raztopina za injiciranje, koncentrat za raztopino za infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
CALCITONINA SANDOZ 50 UI/ml solution for injection and infusion intravenous use, intramuscular use, subcutaneous use 
CALCITONINA SANDOZ 50 i.e./ml raztopina za injiciranje in infundiranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
solution for injection/infusion intravenous use, intramuscular use, subcutaneous use 
raztopina za injiciranje/infundiranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calcitonine Cédiat solution for injection intramuscular use, intravenous use, subcutaneous use 
Calcitonine Cédiat raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Miacalcic 50 IU/ml Ampoules solution for injection subcutaneous use, intramuscular use, intravenous use 
Miacalcic 50 IU/ml Ampoules raztopina za injiciranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
solution for injection subcutaneous use, intramuscular use, intravenous use 
raztopina za injiciranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
Miacalcic 100 IU/1 ml solution for injection, concentrate for solution for infusion subcutaneous use, intramuscular use, intravenous use 
Miacalcic 100 IU/1 ml raztopina za injiciranje, koncentrat za raztopino za infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
Calcitonin 100 Jelfa 
Calcitonin 100 Jelfa injekcija subkutana uporaba
Slovak Republic 
Slovaška
Staporos solution for injection in pre-filled syringe intramuscular use, intravenous use, subcutaneous use 
Staporos raztopina za injiciranje v napolnjeni injekcijski brizgi intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Staporos solution for injection intramuscular use, intravenous use, subcutaneous use 
Staporos raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Cadens solution for injection intramuscular use, intravenous use, subcutaneous use 
Cadens raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Calcitonin 'Novartis' 200 I.E. - Nasalspray 
Calcitonin 'Novartis' 200 I.E. - Nasalspray pršilo za nos, raztopina nazalna uporaba
CALCITONINA SANDOZ 100 UI/ml solution for injection and infusion intravenous use, intramuscular use, subcutaneous use 
CALCITONINA SANDOZ 100 i.e./ml raztopina za injiciranje in infundiranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Calsyn solution for injection intramuscular use, intravenous use, subcutaneous use 
Calsyn raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
50 IU/1ML AMP solution for injection intravenous use, intramuscular use, subcutaneous use 
50 i.e./1 ml amp raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Miacalcic solution for injection subcutaneous use, intramuscular use 
Miacalcic raztopina za injiciranje subkutana uporaba, intramuskularna uporaba
solution for injection intravenous use, intramuscular use, subcutaneous use 
raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Miacalcic 100 IU/ml Ampoules solution for injection subcutaneous use, intramuscular use, intravenous use 
Miacalcic 100 IU/ml Ampoules raztopina za injiciranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
solution for injection intramuscular use, subcutaneous use 
raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
100 IU/1ML AMP solution for injection intravenous use, intramuscular use, subcutaneous use 
100 i.e./1 ML amp raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Miacalcic solution for injection/infusion intramuscular use, intravenous use, subcutaneous use 
Miacalcic raztopina za injiciranje/infundiranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
solution for Injection/infusion intramuscular use, subcutaneous use 
raztopina za injiciranje/infundiranje intramuskularna uporaba, subkutana uporaba
Miacalcic solution for injection intramuscular use, intravenous use, subcutaneous use 
Miacalcic raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Calcitonin 'Novartis' 100 I.E. - Nasalspray 
Calcitonin 'Novartis' 100 I.E. - Nasalspray pršilo za nos, raztopina nazalna uporaba
solution for injection intramuscular use, intravenous use, subcutaneous use 
raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
100 IU/1ML AMP solution for injection intramuscular use, subcutaneous use 
100 i.e./1 ml amp raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
200UI/1d. 
200 i.e.
100 IU 
100 i.e.
Miacalcic solution for injection intramuscular use, subcutaneous use 
Miacalcic raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
Miacalcic solution for injection/infusion subcutaneous use, intramuscular use 
Miacalcic raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba
Miacalcic Nasal 200 200 IU/dose nasal spray nasal use 
Miacalcic Nasal 200 200 i.e./odmerek pršilo za nos nazalna uporaba
50 IU 
50 i.e.
Miacalcic solution for injection/infusion intramuscular use, subcutaneous use 
Miacalcic raztopina za injiciranje/infundiranje intramuskularna uporaba, subkutana uporaba
Calcitonin Stada 100 I.E. Injektionslösung 100 IU / 1 ml solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin Stada 100 I.E. Injektionslösung raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
Miacalcic solution for injection intravenous use subcutaneous use, intramuscular use 
Miacalcic raztopina za injiciranje intravenska uporaba, subkutana uporaba, intramuskularna uporaba
100 i.e./ml solution for injection/infusion subcutaneous use, intramuscular use, intravenous use 
100 i.e./1 ml amp raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
blister (alu/alu) 
pretisni omot (alu/alu)
Pack size bottle (HDPE) 
Velikost pakiranja plastenka (HDPE)
Route of Administration 
Pot uporabe
EU Number 
Številka EU
Route of Administration vial (glass) 
Viala (steklo)
Strength Pharmaceutical Form 
Izmišljeno ime Jakost Farmacevtska oblika
Medicinal Product no longer authorised 
Zdravilo nima veā dovoljenja za promet
1 pre-filled syringe with needleguard + 1 alcohol pad 
1 napolnjena injekcijska brizga s ščitnikom za iglo + 1 alkoholni zloženec
1 vial + 1 syringe + 2 alcohol pads 
1 injekcijska brizga + 2 alkoholna zloženca
1 pre-filled syringe + 1 alcohol pad 
6 napolnjenih injekcijskih peresnikov + 6 alkoholnih zložencev
In doubtful cases, patients should be referred to a neurologist for appropriate investigations. 
V dvomljivih primerih je treba bolnike napotiti k nevrologu za izvedbo ustreznih preiskav.
Children and adolescents <invented name> is not recommended in children aged below 18 years. 
Otroci in mladostniki Zdravilo <Izmišljeno ime> ni priporočeno pri otrocih, starih do 18 let.
Anti-ischemic effects are achieved without concomitant haemodynamic effects. 
Protiishemični učinki so doseženi brez sočasnega hemodinamičnega učinka.
The majority of the patients recovered within 4 months after trimetazidine withdrawal. 
Večina bolnikov je v štirih mesecih po prenehanju jemanja trimetazidina okrevala.
Paediatric population: 
Pediatrična populacija:
A significant difference was also evidenced for the time to onset of angina pectoris (p=0.049). 
Značilna razlika je bila dokazana tudi za čas do nastopa angine pektoris (p=0,049).
How to take <invented name> 
Kako jemati zdravilo <Izmišljeno ime>
These cases have a low incidence and are usually reversible after treatment discontinuation. 
Prevalenca teh primerov je nizka in običajno so reverzibilni po ukinitvi zdravljenja.
If parkinsonian symptoms persist more than 4 months after drug discontinuation, a neurologist opinion should be sought. 
Če so simptomi Parkinsonove bolezni prisotni več kot štiri mesece po prenehanju jemanja zdravila, je treba pridobiti mnenje nevrologa.
The safety and efficacy of trimetazidine in children aged below 18 years have not been established. 
Varnost in učinkovitost trimetazidina pri otrocih, starih do 18 let, še nista bili dokazani.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
A. Summary of Products Characteristics 
A. Povzetek glavnih značilnosti zdravila
4.8 Undesirable effects [the wording below should be inserted] 
4.8 Neželeni učinki [vstaviti je treba naslednje besedilo]
Elderly patients 
Starejši bolniki:
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflet 
Priloga III Dopolnitve ustreznih poglavij povzetka glavnih značilnosti zdravila in navodila za uporabo
[the wording below should be inserted in the relevant sections] 
[spodnje besedilo je treba vstaviti v ustrezna poglavja]
Trimetazidine does not have haemodynamic effects in clinical studies, however cases of dizziness and drowsiness have been observed in post-marketing experience (see section 4.8), which may affect ability to drive and use machines. 
Trimetazidin v kliničnih študijah ni imel hemodinamičnih učinkov, so pa v času po prihodu zdravila na trg opazili primere omotice in zaspanosti (glejte poglavje 4.8), ki lahko vplivata na sposobnost vožnje in upravljanja s stroji.
Caution should be exercised when prescribing trimetazidine to patients in whom an increased exposure is expected: - moderate renal impairment (see sections 4.2 and 5.2), - elderly patients older than 75 years old (see section 4.2) 
Pri predpisovanju zdravila bolnikom, pri katerih je predvidena povečana izpostavljenost trimetazidinu, je potrebna previdnost: - z zmerno ledvično okvaro (glejte poglavji 4.2 in 5.2); - starejšim bolnikom, starim nad 75 let (glejte poglavje 4.2).
Falls may occur, related to gait instability or hypotension, in particular in patients taking antihypertensive treatment (see section 4.8). 
Lahko se pojavijo padci, povezani z nestabilno hojo ali hipotenzijo, zlasti pri bolnikih, zdravljenih z antihipertenzivi (glejte poglavje 4.8).
Clinical studies have demonstrated the efficacy and safety of trimetazidine in the treatment of patients with chronic angina, either alone or when the benefit from other antianginal medicinal products was insufficient. 
Klinične študije so dokazale učinkovitost in varnost trimetazidina pri zdravljenju bolnikov s kronično angino pektoris, bodisi kot samostojnega zdravila ali ko je bilo zdravljenje z drugimi antianginoznimi zdravili nezadostno.
In an ischaemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in the β-oxidation process. 
V ishemični celici pridobivanje energije z oksidacijo glukoze zahteva manjšo porabo kisika kot z -oksidacijo.
Always take this medicine exactly as your doctor has told you. 
Pri jemanju tega zdravila natančno upoštevajte navodila svojega zdravnika.
[the currently approved indications should be deleted and replaced by the following] 
[trenutno odobrene indikacije je treba izbrisati ter jih nadomestiti z naslednjo]
Dose titration in elderly patients should be exercised with caution (see section 4.4). 
Prilagoditev odmerka je pri starejših bolnikih treba opraviti s previdnostjo (glejte poglavje 4.4).
This medicine may make you feel dizzy and drowsy that may affect your ability to drive or use machinery. 
Vpliv na sposobnost upravljanja vozil in strojev To zdravilo lahko povzroči omotico ali zaspanost, ki lahko vplivata na vašo sposobnost vožnje in upravljanja strojev.
Trimetazidine inhibits β-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. 
Trimetazidin zavira -oksidacijo maščobnih kislin preko zaviranja dolgoverižne-3-ketoacil-CoA tiolaze, kar posledično poveča oksidacijo glukoze.
Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia. 
Okrepitev oksidacije glukoze optimira energijske procese v celici, s čimer se v času ishemije ohranja ustrezna presnova energije.
In the overall population, including both asymptomatic and symptomatic patients, trimetazidine failed to demonstrate a benefit on both ergometric (total exercise duration, time to onset of 1mm ST and time to onset angina) and clinical endpoints. 
Pri celotni populaciji, ki je vključevala asimptomatske in simptomatske bolnike, niso uspeli dokazati prednosti trimetazidina niti pri ergometričnih (trajanje celotne vadbe, čas do nastopa za 1 mm znižane veznice ST in čas do nastopa angine pektoris) niti pri kliničnih opazovanih dogodkih.
The dose is one tablet of 35mg of trimetazidine twice daily during meals. 
Odmerek je ena tableta s 35 mg trimetazidina dvakrat dnevno med obrokom.
Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies. 
Trimetazidin je pri odraslih bolnikih indiciran kot dodatno zdravilo za simptomatsko zdravljenje bolnikov s stabilno angino pektoris, pri katerih z zdravili prve izbire te bolezni ni mogoče zadovoljivo nadzorovati oziroma bolniki zdravljenja z njimi ne prenašajo.
Arterial Hypotension , Orthostatic hypotension that may be associated with malaise, dizziness or fall, in particular in patients taking antihypertensive treatment, flushing 
Žilne bolezni redki arterijska hipotenzija, ortostatska hipotenzija, ki je lahko povezana s splošnim slabim počutjem, omotico ali padcem, zlasti pri bolnikih, zdravljenih z antihipertenzivi, zardevanje
If you get any side effects, talk to your doctor or pharmacist. 
Če ste negotovi, se posvetujte s svojim zdravnikom ali s farmacevtom.
Patients with renal impairment 
Bolniki z ledvično okvaro:
In a 426-patients randomized, double blind, placebo-controlled study (TRIMPOL-II), trimetazidine (60mg/day) added to metoprolol 100mg daily (50 mg b.i.d) for 12 weeks significantly improved statistically exercise tests parameters and clinical symptoms as compared to placebo: total exercise duration +20.1s, p= 0.023, total workload +0.54 METs, p=0.001, time to 1-mm ST-segment depression +33.4s, p=0.003, time to onset of angina +33.9s, p<0.001, angina attacks/week -0.73, p=0.014 and short acting nitrates consumption/week, -0.63, p=0.032, without hemodynamic changes. 
V randomizirani, dvojno slepi, s placebom nadzorovani študiji pri 426 bolnikih (TRIMPOL-II) je trimetazidin (60 mg/dan) poleg metoprolola v odmerku 100 mg dnevno (50 mg dvakrat dnevno) v 12 tednih statistično značilno izboljšal parametre obremenitvenih testov in klinične simptome v primerjavi s placebom: trajanje celotne vadbe +20,1 s, p = 0,023, skupna obremenitev +0,54 MET, p = 0,001, čas do nastopa za 1 mm znižane veznice ST +33,4 s, p = 0,003, čas do nastopa angine pektoris +33,9 s, p < 0,001, število anginoznih napadov/teden -0,73, p = 0,014, in poraba kratko delujočih nitratov/teden, -0,63, p = 0,032, brez hemodinamičnih sprememb.
Elderly patients may have increased trimetazidine exposure due to age-related decrease in renal function (see section 5.2). 
Pri starejših bolnikih je zaradi s starostjo povezanega zmanjšanega delovanja ledvic izpostavljenost trimetazidinu lahko večja (glejte poglavje 5.2).
What you need to know before you take <invented name> Do not take <invented name> - if you are allergic to trimetazidine or any of the other ingredients of this medicine (listed in section - if you have a Parkinson disease: disease of the brain affecting movement (trembling, rigid posture, 
Ne jemljite zdravila <Izmišljeno ime> - če ste alergični na trimetazidin ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če imate Parkinsonovo bolezen: bolezen možganov, ki vpliva na gibanje (tresenje, okorela drža, počasni gibi in negotova, neuravnotežena hoja), - če imate hude težave z ledvicami.
The occurrence of movement disorders such as parkinsonian symptoms, restless leg syndrome, tremors, gait instability should lead to definitive withdrawal of trimetazidine. 
V primeru pojava motenj gibanja, kot so simptomi Parkinsonove bolezni, sindrom nemirnih nog, tremor, nestabilna hoja, je treba zdravljenje s trimetazidinom dokončno ukiniti.
What <invented name>is and what it is used for This medicine is intended for use in adult patient, in combination with other medicines to treat angina pectoris (chest pain caused by coronary disease). 
To zdravilo je pri odraslih bolnikih skupaj z drugimi zdravili namenjeno za zdravljenje angine pektoris (bolečine v prsih, ki jo povzroča koronarna bolezen).
Palpitations, extrasystoles, tachycardia 
Srčne bolezni redki palpitacije, ekstrasistole, tahikardija
This medicine can cause or worsen symptoms such as trembling, rigid posture, slow movements and a shuffling, unbalanced walk, especially in elderly patients, which should be investigated and reported to your doctor who could reassess the treatment. 
To zdravilo lahko povzroči ali poslabša simptome, kot so tresenje, okorela drža, počasni gibi in negotova, neuravnotežena hoja, zlasti pri starejših bolnikih.
In a 1962 patients three-month randomised, double-blinded study (Vasco study) on top of atenolol 50 mg/d, two dosages of trimetazidine (70 mg/d and 140 mg/d) were tested versus placebo. 
V randomizirani, dvojno slepi trimesečni študiji pri 1962 bolnikih (študija VASCO) so dve odmerjanji trimetazidina (70 mg/dan in 140 mg/dan) poleg atenolola 50 mg/dan primerjali s placebom.
The recommended dose of <invented name> 35mg is one tablet to be taken two times a day during meals in the morning and evening. 
Priporočeni odmerek zdravila <Izmišljeno ime> 35 mg je ena tableta dvakrat na dan med obrokom, zjutraj in zvečer.
However, in the subgroup of symptomatic patients (n= 1574) defined in a post-hoc analysis, trimetazidine (140 mg) significantly improved total exercise duration (+23.8 s versus +13.1 s placebo; p=0.001) and time to onset of angina (+46.3 s versus +32.5 s placebo; p=0.005). 
Kljub temu je trimetazidin (140 mg) pri podskupini simptomatskih bolnikov (n=1574), določeni v naknadni analizi, značilno izboljšal trajanje celotne vadbe (+23,8 s v primerjavi s +13,1 s pri placebu; p=0,001) in čas do nastopa angine pektoris (+46,3 s v primerjavi s +32,5 s pri placebu; p=0,005).
Driving and using machines 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
Sleep disorders (insomnia, drowsiness) 
Bolezni živčevja neznana pogostnost motnje spanja (nespečnost, zaspanost)
In patients with ischaemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels. 
Trimetazidin pri bolnikih z ishemično boleznijo srca deluje na presnovo celic srčne mišice in v njih ohranja visoko raven energetsko bogatih fosfatov.
4.3 Contraindications [the currently approved contraindications should be deleted and replaced by the following] 
[trenutno odobrene kontraindikacije je treba izbrisati ter jih nadomestiti z naslednjimi]
Trimetazidine can cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), which should be regularly investigated, especially in elderly patients. 
Trimetazidin lahko povzroči ali poslabša simptome Parkinsonove bolezni (tremor, akinezijo, hipertonijo).
B. Package Leaflet 
B. Navodilo za uporabo
Acute generalized exanthematus pustulosis (AGEP), angioedema 
Bolezni kože in podkožja neznana pogostnost akutna generalizirana eksantematozna pustuloza (AGEP), angioedem
The dose is one tablet of 20mg or 1 ml (20 drops) of oral drop solution of trimetazidine three times a day during meals. 
Odmerek je ena tableta z 20 mg trimetazidina ali 1 ml (20 kapljic) peroralne raztopine trimetazidina trikrat dnevno med obrokom.
The recommended dose of <invented name> 20mg/ml solution is 20 drops to be taken three times a day during meals. 
Priporočeni odmerek zdravila <Izmišljeno ime> 20 mg/ml raztopina je 20 kapljic trikrat na dan med obrokom.
No significant difference between groups could be found for the other secondary endpoints (total exercise duration, total workload and clinical endpoints). 
Za druge sekundarne opazovane dogodke (trajanje celotne vadbe, skupno obremenitev in klinične opazovane dogodke) med skupinama niso našli značilnih razlik.
Parkinsonian symptoms (tremor, akinesia, hypertonia), gait instability, restlessleg syndrome, other related movement disorders, usually reversible after treatment discontinuation 
Prednostni izraz omotica, glavobol neznana pogostnost simptomi Parkinsonove bolezni (tremor, akinezija, hipertonija), nestabilna hoja, sindrom nemirnih nog, druge podobne motnje gibanja, simptomi so običajno reverzibilni po prekinitvi zdravljenja